ZIOPHARM Oncology downgraded by Jefferies Financial Group
$ZIOP
Biotechnology: Pharmaceutical Preparations
Health Care
Jefferies Financial Group downgraded ZIOPHARM Oncology from Buy to Hold
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/9/2021 | $3.00 → $2.00 | Market Perform | Raymond James |
| 8/10/2021 | Outperform → Mkt Perform | Raymond James | |
| 8/10/2021 | $3.00 | Outperform → Market Perform | Raymond James |
SHANGHAI and BOSTON, April 7, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr. Raffaele Baffa ("Dr. Baffa") has been appointed as the Chief Medical Officer ("CMO") of the Company, responsible for overseeing the global clinical development strategies and operations for the Company's innovative pipeline product candidates. Dr. Baffa will report to Dr. Zonghai Li, Founder, Chairman of the Board, CEO, CSO of CARsgen Therapeutics Holdings Limited. Dr. Baffa has rich experiences in pharmaceutical industry and research institutes,
– Mr. Huang is a veteran industry entrepreneur with 20+ years founding and funding biotech innovation – – Heidi Hagen elected Lead Independent Director – BOSTON, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP) today announced the election of James Huang as Chairman of the Board of Directors (the “Board”), effective immediately. Mr. Huang has served on the Board since July 2020 and is currently a Managing Partner at Kleiner Perkins Caufield & Byers (KPCB) China. He has founded and financed several innovative life sciences companies, including GenScript, Legend Biotech and Zai Lab. He is also Founding Partner of Panacea Venture, which
Has Held Several Discussions with WaterMill to Reach an Amicable Resolution to Consent Solicitation Board Accepts Resignation of Director Elan Ezickson Reiterates Concerns About Professional Past of WaterMill Nominee Holger Weis BOSTON, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today announced that it has sent a letter to shareholders urging them to support the Company’s continued progress and long-term prospects. The letter was sent in connection with the Company’s definitive consent revocation statement in response to the consent solicitation initiated by WaterMill Asset
Raymond James reiterated coverage of ZIOPHARM Oncology with a rating of Market Perform and set a new price target of $2.00 from $3.00 previously
Raymond James downgraded ZIOPHARM from Outperform to Mkt Perform
Raymond James downgraded ZIOPHARM Oncology from Outperform to Market Perform and set a new price target of $3.00
8-K - Alaunos Therapeutics, Inc. (0001107421) (Filer)
8-K - ZIOPHARM ONCOLOGY INC (0001107421) (Filer)
10-Q - ZIOPHARM ONCOLOGY INC (0001107421) (Filer)
Ziopharm Ocology Inc (NASDAQ:ZIOP) has rebranded itself and has changed its name to Alaunos Therapeutics Inc. The Company will trade on NASDAQ under the new ticker symbol "TCRT" to be effective tomorrow. Along with the name change, the Company amended Phase 1/2 IND to add four additional T-cell receptors (TCRs) to its library, increasing the number of eligible patients for the clinical trial. Related: Ziopharm Shares Are Trading Lower After Slashing Workforce By Over 50%. Phase 1/2 TCR-T library trial targeting KRAS, TP53, and EGFR mutations across six solid tumor indications is open for enrollment at Texas' MD Anderson Cancer Center. Dosing is expected to start in 1H of 2022. Additi
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Gilead Hit With FDA Partial Clinical Hold On Multiple Blood Cancer Studies Evaluating Magrolimab-Vidaza Combo Gilead Sciences, Inc. (NASDAQ:GILD) said the U.S. Food and Drug Administration has placed a partial clinical hold on studies evaluating the combination of magrolimab plus Bristol-Myers Squibb Co's (NYSE:BMY) Vidaza due to an apparent imbalance in investigator-reported suspected unexpected serious adverse reactions between study arms. While no clear trend in the adverse reactions or new safety signal has been identified by Gilead at this time, the partial clinical hold is being implem
Phase 1/2 TCR-T Library trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications is open for enrollment; continue to expect to dose the first patient in 1H 2022 Phase 1/2 IND amended to include four additional TCRs, bringing the total number of evaluable TCRs to 10, further expanding number of eligible patients In-house cGMP manufacturing facility is operational to support internal clinical development programs Company changes name to Alaunos Therapeutics reflecting renewed focus HOUSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (NASDAQ:ZIOP), a clinical-stage oncology-focused cell therapy comp
SHANGHAI and BOSTON, April 7, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr. Raffaele Baffa ("Dr. Baffa") has been appointed as the Chief Medical Officer ("CMO") of the Company, responsible for overseeing the global clinical development strategies and operations for the Company's innovative pipeline product candidates. Dr. Baffa will report to Dr. Zonghai Li, Founder, Chairman of the Board, CEO, CSO of CARsgen Therapeutics Holdings Limited. Dr. Baffa has rich experiences in pharmaceutical industry and research institutes,
Phase 1/2 TCR-T Library trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications is open for enrollment; continue to expect to dose the first patient in 1H 2022 Phase 1/2 IND amended to include four additional TCRs, bringing the total number of evaluable TCRs to 10, further expanding number of eligible patientsIn-house cGMP manufacturing facility is operational to support internal clinical development programsCompany changes name to Alaunos Therapeutics reflecting renewed focus HOUSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), a clinical-stage oncology-focused cell therapy company, today highlighted rec
HOUSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today announced the presentation of preclinical data highlighting the potential of neoantigen-specific TCR-T cells for the treatment of solid tumors at the Society for Immunotherapy of Cancer 2021 Annual Meeting. "We are pleased to share preclinical data demonstrating the versatility of our Sleeping Beauty technology to develop neoantigen-specific TCR-T cells with the potential to address a wide range of solid tumor indications," commented Raffaele Baffa, M.D., Ph.D., Chief Medical Officer & EVP, Research & Development. "Our TCR-T library approach allows us to develop safe, effe
HOUSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today announced financial results for the third quarter ended September 30, 2021 and provided a business update. "I am impressed by the quality and dedication of our team at Ziopharm who all are diligently working to transform our cutting-edge scientific research into meaningful clinical progress. Last quarter we made the decision to restructure the organization and focus our efforts on advancing our differentiated TCR-T library towards the clinic," said Kevin S. Boyle, Sr., Chief Executive Officer at Ziopharm Oncology. "We are making excellent progress to operationa
HOUSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today announced that it will report financial results for the third quarter ended September 30, 2021 on Monday, November 8, 2021, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 4:30 p.m. ET to provide a corporate update and review the financial results. The conference call can be accessed by dialing 877-451-6152 (United States) or 201-389-0879 (International) with the conference code 13724384. A live webcast may be accessed using the link here, or by visiting the "Investors" section of the Ziopharm website at w
Mr. Boyle brings over 20 years of executive business leadership in CEO, CFO and operational leadership roles Strong track record of successfully guiding companies and creating shareholder value through disciplined capital management and achievement of milestones Raffaele Baffa MD, Ph.D. appointed Head of Research and Development in addition to Chief Medical Officer Adam Levy, Ph.D., MBA appointed Executive Vice President, Corporate Development and Investor Relations Conference call scheduled for today at 4:30 pm EDT BOSTON and HOUSTON, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today announced the appointment of Kevin S. Boyl
4 - ZIOPHARM ONCOLOGY INC (0001107421) (Issuer)
4 - ZIOPHARM ONCOLOGY INC (0001107421) (Issuer)
3 - ZIOPHARM ONCOLOGY INC (0001107421) (Issuer)
SC 13G/A - ZIOPHARM ONCOLOGY INC (0001107421) (Subject)
SC 13G/A - ZIOPHARM ONCOLOGY INC (0001107421) (Subject)
SC 13G/A - ZIOPHARM ONCOLOGY INC (0001107421) (Subject)